Partnerships and Anti-Infective Efforts
Anti-infective Efforts - Sharing azithromycin data:
In an effort to share information that could benefit COVID-19 mitigation efforts, Pfizer researchers published a review in Clinical Pharmacology and Therapeutics which assesses published in vitro and clinical data regarding azithromycin as an agent with antiviral properties. This open access review may serve to facilitate the use of azithromycin in future research on COVID-19. Azithromycin is not approved for the treatment of viral infections.
Research that may inform future vaccination guidelines
Pfizer Inc. and the Liverpool School of Tropical Medicine’s Respiratory Infection Clinical Research Group launched two new studies to provide insights on the interaction between S. pneumoniae and SARS-CoV-2. Pfizer's collaboration agreement with Liverpool provides funding and in-kind laboratory testing support for this research.